Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
iTeos Therapeutics, Inc. - Common Stock
(NQ:
ITOS
)
7.405
-0.065 (-0.87%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about iTeos Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
December 12, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos to Participate in Upcoming Investor Conferences
November 26, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 12, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
October 24, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
September 14, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos to Participate in Upcoming Investor Conferences
August 28, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
August 20, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 08, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
August 05, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
July 08, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
June 17, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
May 10, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Therapeutics Announces $120 Million Registered Direct Offering
May 10, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
April 07, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
March 06, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
March 06, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
March 05, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos to Participate in Upcoming Investor Conferences
March 01, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Announces 2024 Strategic Priorities and Anticipated Milestones
January 08, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 07, 2023
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos to Participate in Upcoming Investor Conferences
September 06, 2023
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 08, 2023
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
June 08, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – June 8, 2023 – USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making...
Via
FinancialNewsMedia
iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates
May 10, 2023
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 15, 2023
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos to Present at Cowen 43rd Annual Health Care Conference
February 28, 2023
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos to Present at SVB Securities Global Biopharma Conference
February 07, 2023
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
iTeos Provides Business Updates and Clinical Development Plans for 2023
January 09, 2023
From
iTeos Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
